The MATRIX trial
Lancet
.
2019 May 4;393(10183):1802-1803.
doi: 10.1016/S0140-6736(19)30040-6.
Authors
Torsten M Meyer
1
,
Markus Hollenbeck
2
,
Jan T Kielstein
3
Affiliations
1
Dialysis Access Center, Academic Teaching Hospital Braunschweig, Braunschweig 38126, Germany; Medical Clinic V, Nephrology Rheumatology, Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Germany.
2
Department of Nephrology and Rheumatology, Dialysis Access Center, Bottrop, Germany.
3
Dialysis Access Center, Academic Teaching Hospital Braunschweig, Braunschweig 38126, Germany. Electronic address: j.kielstein@klinikum-braunschweig.de.
PMID:
31057163
DOI:
10.1016/S0140-6736(19)30040-6
No abstract available
Publication types
Letter
Comment
MeSH terms
Acute Coronary Syndrome*
Heparin*
Hirudins
Humans
Peptide Fragments
Recombinant Proteins
Substances
Hirudins
Peptide Fragments
Recombinant Proteins
Heparin
bivalirudin